Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 145.48
(1.29%)
INR 145.48
(1.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -941.8 Million INR | -724.12% |
| 2022 | 150.9 Million INR | -80.65% |
| 2021 | 779.89 Million INR | -65.66% |
| 2020 | 2.27 Billion INR | 233.97% |
| 2019 | 679.92 Million INR | 5186.7% |
| 2018 | 12.86 Million INR | -38.22% |
| 2017 | 20.81 Million INR | 103.44% |
| 2016 | -604.46 Million INR | -216.81% |
| 2015 | 517.47 Million INR | 905.77% |
| 2014 | -64.22 Million INR | -224.07% |
| 2013 | 51.76 Million INR | -93.02% |
| 2012 | 741.48 Million INR | 19.95% |
| 2011 | 618.16 Million INR | 5726.84% |
| 2010 | 10.6 Million INR | 132.92% |
| 2009 | -32.23 Million INR | -369.51% |
| 2008 | 11.95 Million INR | 1167.77% |
| 2007 | -1.12 Million INR | -717.52% |
| 2006 | -137 Thousand INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 867.1 Million INR | -44.82% |
| 2024 Q1 | 1.57 Billion INR | 266.84% |
| 2023 Q2 | 129 Million INR | -96.79% |
| 2023 Q4 | -941.8 Million INR | -125.73% |
| 2023 FY | -941.8 Million INR | -724.12% |
| 2023 Q3 | 3.66 Billion INR | 2737.98% |
| 2023 Q1 | 4.02 Billion INR | 2567.15% |
| 2022 Q1 | 128.8 Million INR | -83.48% |
| 2022 FY | 150.9 Million INR | -80.65% |
| 2022 Q4 | 150.9 Million INR | 260.14% |
| 2022 Q3 | 41.9 Million INR | -97.8% |
| 2022 Q2 | 1.9 Billion INR | 1378.96% |
| 2021 Q2 | 968 Million INR | 514.99% |
| 2021 Q4 | 779.89 Million INR | -6.03% |
| 2021 Q1 | 157.4 Million INR | -93.07% |
| 2021 Q3 | 829.9 Million INR | -14.27% |
| 2021 FY | 779.89 Million INR | -65.66% |
| 2020 FY | 2.27 Billion INR | 233.97% |
| 2020 Q1 | 89.5 Million INR | -86.84% |
| 2020 Q2 | 1.05 Billion INR | 1074.64% |
| 2020 Q3 | 257.7 Million INR | -75.49% |
| 2020 Q4 | 2.27 Billion INR | 781.17% |
| 2019 Q1 | 2.1 Billion INR | 16300.4% |
| 2019 Q4 | 679.92 Million INR | 20.75% |
| 2019 FY | 679.92 Million INR | 5186.7% |
| 2019 Q2 | 81.7 Million INR | -96.13% |
| 2019 Q3 | 563.1 Million INR | 589.23% |
| 2018 Q4 | 12.86 Million INR | -99.1% |
| 2018 Q2 | 8.6 Million INR | -99.21% |
| 2018 Q3 | 1.43 Billion INR | 16569.77% |
| 2018 Q1 | 1.08 Billion INR | 5130.8% |
| 2018 FY | 12.86 Million INR | -38.22% |
| 2017 Q1 | 798.6 Million INR | 232.12% |
| 2017 FY | 20.81 Million INR | 103.44% |
| 2017 Q4 | 20.81 Million INR | -97.06% |
| 2017 Q3 | 709.29 Million INR | 0.0% |
| 2017 Q2 | - INR | -100.0% |
| 2016 Q1 | 127.48 Million INR | -75.36% |
| 2016 Q4 | -604.46 Million INR | -132.32% |
| 2016 FY | -604.46 Million INR | -216.81% |
| 2016 Q3 | 1.87 Billion INR | 201.21% |
| 2016 Q2 | -1.84 Billion INR | -1549.58% |
| 2015 Q3 | 67.7 Million INR | -45.4% |
| 2015 FY | 517.47 Million INR | 905.77% |
| 2015 Q2 | 124 Million INR | -28.51% |
| 2015 Q1 | 173.44 Million INR | 370.07% |
| 2015 Q4 | 517.47 Million INR | 664.36% |
| 2014 Q4 | -64.22 Million INR | -184.61% |
| 2014 Q1 | 130.55 Million INR | 152.23% |
| 2014 FY | -64.22 Million INR | -224.07% |
| 2014 Q2 | -43.1 Million INR | -133.01% |
| 2014 Q3 | 75.89 Million INR | 276.1% |
| 2013 Q1 | 1.03 Billion INR | 39.76% |
| 2013 Q2 | 512.5 Million INR | -50.55% |
| 2013 Q4 | 51.76 Million INR | -88.74% |
| 2013 Q3 | 459.7 Million INR | -10.3% |
| 2013 FY | 51.76 Million INR | -93.02% |
| 2012 Q4 | 741.48 Million INR | 0.0% |
| 2012 FY | 741.48 Million INR | 19.95% |
| 2011 FY | 618.16 Million INR | 5726.84% |
| 2011 Q4 | 618.16 Million INR | 0.0% |
| 2010 FY | 10.6 Million INR | 132.92% |
| 2009 FY | -32.23 Million INR | -369.51% |
| 2008 FY | 11.95 Million INR | 1167.77% |
| 2007 FY | -1.12 Million INR | -717.52% |
| 2006 FY | -137 Thousand INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 124.362% |
| Hester Biosciences Limited | 2.29 Billion INR | 141.113% |
| Aarti Drugs Limited | 5.54 Billion INR | 116.974% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 136.058% |
| Albert David Limited | -278.36 Million INR | -238.328% |
| Alembic Limited | 66.9 Million INR | 1507.773% |
| Alkem Laboratories Limited | -1.6 Billion INR | 41.481% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 509.598% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 128.548% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -5005.714% |
| Brooks Laboratories Limited | 49.48 Million INR | 2003.203% |
| Eris Lifesciences Limited | 13.8 Billion INR | 106.821% |
| FDC Limited | -57.75 Million INR | -1530.766% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 66.869% |
| Gufic Biosciences Limited | 3.19 Billion INR | 129.484% |
| Hikal Limited | 7.96 Billion INR | 111.821% |
| Ind-Swift Limited | 9.5 Billion INR | 109.905% |
| Innova Captab Limited | 2.33 Billion INR | 140.355% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 14.483% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 32.241% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 103.479% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -637.868% |
| Lupin Limited | 19.38 Billion INR | 104.858% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 196.515% |
| Medico Remedies Limited | 78.67 Million INR | 1297.046% |
| Morepen Laboratories Limited | -231.17 Million INR | -307.399% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 115.296% |
| Orchid Pharma Limited | -1.31 Billion INR | 28.317% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 59.889% |
| RPG Life Sciences Limited | -364.7 Million INR | -158.24% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 884.578% |
| Sigachi Industries Limited | 859.94 Million INR | 209.518% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 109.388% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 749.625% |
| Themis Medicare Limited | 764.96 Million INR | 223.117% |
| Unichem Laboratories Limited | 931.91 Million INR | 201.061% |
| Vaishali Pharma Limited | 119.13 Million INR | 890.532% |
| Wanbury Limited | 1.1 Billion INR | 185.163% |
| Windlas Biotech Limited | -273.04 Million INR | -244.931% |
| ZIM Laboratories Limited | 983.6 Million INR | 195.75% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 77.323% |
| Ipca Laboratories Limited | 11.41 Billion INR | 108.25% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.7% |
| Venus Remedies Limited | -267.7 Million INR | -251.812% |
| Sakar Healthcare Limited | 790.93 Million INR | 219.074% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 125.5% |
| Divi's Laboratories Limited | -39.77 Billion INR | 97.632% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 81.211% |
| Mankind Pharma Limited | -1.74 Billion INR | 46.132% |
| Sequent Scientific Limited | 4.17 Billion INR | 122.538% |
| Laurus Labs Limited | 24.35 Billion INR | 103.867% |
| Neuland Laboratories Limited | -214.05 Million INR | -339.974% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 133.383% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 78.022% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 124.075% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -278.549% |
| Wockhardt Limited | 18.27 Billion INR | 105.155% |
| Bal Pharma Limited | 1.26 Billion INR | 174.535% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 107.293% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 18.653% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -156.944% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 82.9% |
| Shilpa Medicare Limited | 9.06 Billion INR | 110.384% |
| Valiant Laboratories Limited | 649.9 Million INR | 244.914% |
| Ajanta Pharma Limited | -954.9 Million INR | 1.372% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 416.487% |
| Granules India Limited | 9.28 Billion INR | 110.141% |
| Medicamen Biotech Limited | 160.31 Million INR | 687.465% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 2138.043% |
| Piramal Enterprises Limited | 491.39 Billion INR | 100.192% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 102.959% |
| NATCO Pharma Limited | -5.81 Billion INR | 83.81% |
| Suven Life Sciences Limited | -1.63 Billion INR | 42.316% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 148.724% |
| Strides Pharma Science Limited | 23.25 Billion INR | 104.05% |
| Indoco Remedies Limited | 6.47 Billion INR | 114.542% |
| Alpa Laboratories Limited | 35.36 Million INR | 2763.236% |
| Lasa Supergenerics Limited | 205.79 Million INR | 557.631% |